Del Favero A, Frongillo R F, Menichetti F, Boldrini F, Guerciolini R, Pauluzzi S
Chemioterapia. 1986 Apr;5(2):88-91.
Norfloxacin (NOR) was compared to pipemidic acid (PA) in complicated urinary tract infections (UTIs) caused by pathogens susceptible to both agents to evaluate the antibacterial activity of the new 4-quinolone derivative. Sixty-five patients were randomly allocated to receive NOR or PA, 400 mg bid for 7 days, and the results evaluated for treatment efficacy at 5 weeks after completion of therapy. Overall microbiological cure was significantly greater in NOR-treated patients, as 19 of 26 were cured (73%), compared to only 16 of 39 (41%) in the PA group (p less than 0.05). Failures and relapses, considered together, were significantly (p less than 0.05) less frequent in patients treated with NOR (4/26) than in those receiving PA (18/39). Clinical response was strictly related to microbiological outcome: NOR had a broader antibacterial spectrum than PA and in this study seemed to be more efficacious in the treatment of complicated UTIs caused only by bacteria susceptible to both agents. This may be related to greater antibacterial activity and/or tissue penetration by NOR, which is thus to be preferred, according to the results of our study, in the treatment of complicated UTIs.
在由对诺氟沙星（NOR）和吡哌酸（PA）均敏感的病原体引起的复杂性尿路感染（UTIs）中，对诺氟沙星与吡哌酸进行了比较，以评估这种新型4-喹诺酮衍生物的抗菌活性。65例患者被随机分配接受诺氟沙星或吡哌酸治疗，400mg，每日两次，共7天，并在治疗结束后5周评估治疗效果。接受诺氟沙星治疗的患者总体微生物学治愈率显著更高，26例中有19例治愈（73%），而吡哌酸组39例中仅16例治愈（41%）（p<0.05）。综合考虑，接受诺氟沙星治疗的患者失败和复发的频率显著低于接受吡哌酸治疗的患者（p<0.05）（分别为4/26和18/39）。临床反应与微生物学结果密切相关：诺氟沙星的抗菌谱比吡哌酸更广，在本研究中，对于仅由对两种药物均敏感的细菌引起的复杂性尿路感染，诺氟沙星似乎更有效。这可能与诺氟沙星更强的抗菌活性和/或组织穿透力有关，因此根据我们的研究结果，在治疗复杂性尿路感染时，诺氟沙星更值得首选。
